Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors [bulk RNA-seq]

ABSTRACT: Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors [bulk RNA-seq]

PROVIDER: PRJNA790787 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17278200.fastq.gz	Fastqsanger.gz
	SRR17278201.fastq.gz	Fastqsanger.gz
	SRR17278202.fastq.gz	Fastqsanger.gz
	SRR17278139.fastq.gz	Fastqsanger.gz
	SRR17278140.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 64

Similar Datasets

Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Project description:Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

| PRJNA1051586 | ENA

Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors [scRNA-seq]

Project description:Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors [scRNA-seq]

| PRJNA1051589 | ENA

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors.

Project description:Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.

| S-EPMC10897522 | biostudies-literature

Bulk RNA-seq of IVD-hMDSCs treated upon CD84 ligation

Project description:CD84 is a key marker of PMN-MDSCs in multiple mouse models and patients tumor samples. Increased CD84 expression levels were found in pathophysiological conditions associated with thrombo-inflammation

2024-08-21 | GSE272966 | GEO

Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors [scRNA-seq]

Project description:In this study, we reported the identification of a specific gene signature expressed by mPMN-MDSCs from NSCLC/HNC patients and G-CSF-treated donor (GDs) by bulk-RNA-seq that clearly reflects their metabolic/functional reprogramming. ScRNA-seq experiments further confirmed that the mPMN-MDSC gene signature is significantly enriched in both mNDNs/mLDNs from GDs

2024-03-07 | GSE250001 | GEO

Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors [bulk RNA-seq]

2024-03-07 | GSE191254 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of human multiple myeloma derived CD84 activated M-MDSCs or IgG (control) treated M-MDSCs

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare CD84 activated to control treated primary human M-MDSCs from multiple myeloma patients transcriptome profiling (RNA-seq) to understand the role of CD84 on these cells Methods: mRNA profiles from sorted M-MDSCs from patient bone marrow samples were generated by deep sequencing, in triplicate, using a bulk adaptation of the MARS-Seq protocol.

2021-05-25 | GSE164652 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of human multiple myeloma derived CD84 activated G-MDSCs or IgG (control) treated G-MDSCs

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare CD84 activated to control treated primary human G-MDSCs from multiple myeloma patients transcriptome profiling (RNA-seq) to understand the role of CD84 on these cells Methods: mRNA profiles from sorted G-MDSCs from patient bone marrow samples were generated by deep sequencing, in triplicate, using a bulk adaptation of the MARS-Seq protocol.

2021-05-25 | GSE164651 | GEO

Transcriptome comparison of PMN-MDSCs and and normal neutrophils

Project description:Polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC), also named pathologically activated neutrophil, is a critical component of tumor microenvironment (TME), playing crucial roles in tumor progression and therapy resistance. Here, we compared the transcriptome of PMN-MDSCs from B16 tumor bearing mice and the neutrophils from tumor free mice.

2023-06-26 | GSE199601 | GEO

Surface CD52, CD84 and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-03-07 | GSE250002 | GEO